Krebs Biochemicals to Hold 33rd AGM on Sep 26, 2025; Key Appointments, RPTs, and FY25 Results on Agenda
The announcement details the company's significant financial losses for FY 2024-25, including a net loss of ₹2,693.93 lakh and a negative net worth of ₹14,623.88 lakh, which are material financial indicators. Additionally, key corporate actions such as the appointment of a new Managing Director and CEO, and approval for related party transactions up to ₹120 crore, are significant for the company's future operations and governance.
The announcement includes the notice for the 33rd AGM where the company will adopt its Annual Report for FY 2024-25. The highlights from this report indicate a substantial net loss of ₹2,693.93 lakh and a worsening negative net worth of ₹14,623.88 lakh for the financial year 2024-25, alongside a decrease in total income. These financial results are concerning.
Krebs Biochemicals and Industries Limited will convene its 33rd Annual General Meeting (AGM) on Friday, 26th September 2025, at 11:30 a.m. at its registered office in Visakhapatnam, Andhra Pradesh. Shareholders will consider and adopt the Audited Financial Statements for the financial year 2024-25. * For FY 2024-25, the company reported a Total Income of ₹4,402.08 lakh. * The Profit/Loss After Tax for FY 2024-25 was a loss of ₹2,693.93 lakh. * The Net Worth as of 31st March 2025 was a negative ₹14,623.88 lakh. * Earnings Per Share (EPS) for FY 2024-25 stood at (₹12.49). Other key businesses to be transacted at the AGM include: * Re-appointment of Mr. Avinash Ravi and Mr. Pabitrakumar K Bhattacharyya as directors. * Appointment of Mr. Manish Kumar Jain as a Director and as the Managing Director & CEO for a five-year term from 7th August 2025 to 6th August 2030, with a monthly remuneration of ₹2,50,000. * Approval of Related Party Transactions with Ipca Laboratories Limited up to an aggregate value of ₹120 crore for any given financial year, including FY 2025-26 and 2026-27. * Re-appointment of M/s. Bhavani & Co. as Statutory Auditors for five years and appointment of M/s. Bojanapalli & Associates as Cost Auditors for FY 2025-26 with a remuneration of ₹1,00,000 plus service tax. * Appointment of M/s. DSMR & Associates as Secretarial Auditors for five consecutive financial years from 2025-26 to 2029-30. The company is providing e-voting facility for shareholders. * Remote e-voting will commence on Tuesday, 23rd September 2025, at 09:00 a.m. and conclude on Thursday, 25th September 2025, at 05:00 p.m. * The cut-off date for determining eligible voters is Friday, 19th September 2025.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.